Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast Cancer Symposium 2021.
1. What are the unmet needs in the treatment of advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer? 00:15-01:04
2. Could you tell us a little about elacestrant, its mechanism of action and potential advantages in the treatment of women with ER+, HER- breast cancer? 01:04-01:32
3. What were the aims, design and eligibility criteria of the EMERALD study? 01:32-02:30
4. What were the efficacy and safety findings of the study? 02:30-03:55
5. Could you comment further on the findings in the ESR1 mutation subgroup, and the clinical significance of this? 03:55-04:39
Speaker Disclosure: Aditya Bardia discloses consultancy/advisory board participation for Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly and Foundation Medicine, and contracted research/grant (to institution) from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca and Eli Lilly.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
Share this Video
Related Videos In Breast Cancer
Matthew Goetz, ESMO 2022: MONARCH 3 trial – Interim overall survival results of abemaciclib + NSAI in patients with HR+, HER2- advanced breast cancer
The MONARCH 3 trial led to abemaciclib plus nonsteroidal aromatase inhibitor approval as initial therapy in postmenopausal patients with hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with significant improvement in progression-free survival. Prof. Matthew Goetz (Mayo Clinic, Rochester, MN, USA) joins touchONCOLOGY to discuss what the MONARCH 3 […]
Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer
Dr Sara Tolaney joins touchONCOLOGY to discuss the latest clinical trial highlights in breast cancer, at ESMO 2022. She discusses the overall survival data from the TROPiCS-02 study, investigating sacituzumab govitecan-hziy versus treatment of physician’s choice in participants with HR+/HER2- metastatic breast cancer; and the overall survival data from the phase 3 MONARCH 3 trial, […]
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Amcenestrant is an optimized oral selective ER degrader (SERD), which is being investigated in the AMEERA-3 (NCT04059484), an open-label phase II randomized study. In this touchONCOLOGY interview, Dr Sara Tolaney (Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, Boston, MA, USA) discusses the phase II study, investigating amcenestrant versus endocrine treatment of physician’s choice in patients […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!